Large-scale testing (Phase 3)Study completedNCT01600716
What this trial is testing
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Who this might be right for
Urinary IncontinenceMultiple SclerosisNeurogenic Bladder
Allergan 144